Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > News - strategic review of STEM animal health

<< Previous

Bullboard Posts

Next >>

Comment by RoyMax123on Aug 02, 2023 2:30pm

59 Views

Post# 35569551

RE:RE:RE:News - strategic review of STEM animal health

BTW,

It would be great if they can have a deal where they receive enough cash to clear the debt and survive until the coactiv+ sales are good enough to stop being in red.

But maybe I'm asking for too much.

RoyMax123 wrote:
They are out of cash (or close to) and they owe 5M to Pivot...

That also mean that there's no "Big Pharma" willing to put a significant upfront amount for DispersinB Trials, because they would not have to raise money that way if that were the case.

pibopibopibopib wrote: Yes but STEM begin to make money ????